Mark Dysinger

Glucagon-like peptide 1 quantitation: on the speed and sensitivity of Gyrolab biomarker assays

Mark Dysinger, Senior Scientist, Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, presented ‘Glucagon-Like Peptide 1 (GLP-1) Quantitation: Gyrolab vs Other Detection Platforms' at the 2nd Annual North American Gyrolab Seminar.

The Gyrolab assay speeded up turnaround considerably compared to assays based on ELISA and MSD technology:

  • 3 × faster assay development
  • 3 × shorter assay run time

View Seminar